Day: September 7, 2023

Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patients was drug related All 3 Alport patients (100% response rate) treated with ELX-02 had biopsy confirmed disease regression, suggesting clinical benefit likely with longer treatment duration Significant strategic interest in ZKN-013 following FDA approval to start Phase 1 single ascending dose (SAD) trial WATERTOWN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today provided an update on the continued advancement of ELX-02 for the...

Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose optimization study planning underway, with initiation of dosing expected before the end of 2023, and extension to run in parallel with next-stage Phase 3 studies THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of five upcoming scientific presentations on its investigational drug LX9211, which is being evaluated in clinical trials for the treatment of diabetic peripheral neuropathic pain (DPNP). Data will be shared through four oral presentations and one poster presentation at various global Congresses. Presentations are as follows:NeuPSIG 2023 International Congress on Neuropathic Pain, Sept. 7-9; Lisbon,...

MILWAUKEE, Sept. 07, 2023 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN), today announced that Chief Executive Officer John Batten and Chief Financial Officer Jeff Knutson are presenting at the Sidoti September 2023 Virtual Small-Cap Conference on Thursday, September 21 at 12:00 pm Central. In conjunction with the event, Twin Disc executives will be available to participate in one-on-one meetings with investors registered to attend the conference. The event will be streamed live via a webcast available on the Investor Presentations section of Twin Disc’s website at https://ir.twindisc.com. About Twin DiscTwin Disc, Inc. designs, manufactures and sells marine and heavy-duty off-highway power transmission equipment. Products offered include marine transmissions, azimuth drives, surface drives, propellers and boat management systems,...

IRVING, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or “the Company”) (NASDAQ: XELA, XELAP), a leader in business processing automation (“BPA”) announced today that the Company signed a new customer for its Marketing Execution solution (“XME”). Exela’s customer, a large regional healthcare provider, was using multiple vendors for print, promotional products and branded apparel leading to inefficiencies and escalating costs. The customer also experienced operational issues with reporting, inventory control, and invoicing. Exela’s XME solution will provide real-time reporting, inventory management, and print-on-demand enabling the elimination of over-inventoried items, reducing the cost of carry on their books and eliminating obsolete materials that needed to be discarded. The TCV of the contract is...

Table 1Table 1Chart 1Chart 1Chart 2Chart 2Table 2Table 2All study objectives were met, demonstrating safety across dose groups and confirming efficacy and durability at the selected doses against placebo (lidocaine) and active control (steroid). All RTX doses (7.5 to 20 µg) were well-tolerated, with few severe or serious adverse events (AEs). The majority of reported AEs related to pain post-administration and resolved within hours following treatment. Very few severe AEs were reported across groups (including placebo) with no dose correlation. RTX post-injection administration pain was easily controlled. RTX 20mcg dose outperformed all other dose groups (including the approved drug for this indication (intra-articular corticosteroids)) for efficacy and durability at and beyond 26 weeks post-treatment....

FORT LAUDERDALE, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”), a portfolio company of leading beverage brands, today announced it has entered a (non-binding) Term Sheet to fund acquisitions.  The Credit Facility will act as a credit reservation agreement (up to an undisclosed amount) for multiple acquisitions and will provide acquisition financing at the current Euribor rate plus 1.5% and will mature in 7 to 10 years depending on each individual acquisition. “This Credit Facility is designed to provide the financial backing for us to execute on a key feature of our business strategy, growth through acquisition,” said Robert Nistico, Chief Executive Officer of Splash Beverage Group.  “We have built our organization with the intention...

Shareholders Vote Convincingly Supports Nano Dimension Leadership, Board and Strategy All Murchinson Nominees Rejected by Nano Shareholders Waltham, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension”, “Nano” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, today announced that following its 2023 Annual General Meeting (“the Annual Meeting”), Nano shareholders have voted to re-elect Nano’s highly qualified director nominees – Dr. Yoav Nissan-Cohen, Col. (Ret.) Channa Caspi and Oded Gera – to the Company’s Board of Directors (“the Board”). In addition, shareholders did not approve separate proposals put forth by Murchinson Ltd. (“Murchinson) to remove other...

Miami, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) — Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), today announced the pricing of its public offering of an aggregate of 10,741,139 shares of its common stock (or common stock equivalents), together with accompanying common stock warrants, at a public offering price of $0.4655 per share (or common stock equivalent) and accompanying warrants. Each share of common stock (or common stock equivalent) is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $0.4655 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $0.4655 per share. The Series A-1 warrants will be exercisable beginning on the effective date of stockholder approval of...